An interventional study of Photon Counting Computed Tomography (PCCT) in CAD - Coronary Artery Disease, sponsored by Centro Cardiologico Monzino. Active, not recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Centro Cardiologico Monzino · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Coronary Artery Disease by Centro Cardiologico Monzino — 4 open to participants now, 6 under way, none of them phase 3. Coronary Artery Disease · Centro Cardiologico Monzino.
Among the 11 studies in Coronary Artery Disease by Centro Cardiologico Monzino, this one is one of 2 that started in 2026, is one of 5 with no phase, and was the 10th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →4 of the 11 studies in Coronary Artery Disease by Centro Cardiologico Monzino are open now, in 1 country. Recruiting first, the newest first:
Centro Cardiologico Monzino · Sites in Italy
Ages 18+
Centro Cardiologico Monzino · Sites in Italy
Ages 18+
Centro Cardiologico Monzino · Sites in Italy
Ages 25–60
Centro Cardiologico Monzino · Sites in Italy
Ages 18+
By country, each count listing its studies:
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 300 is above the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 200 across the 6 interventional studies, 400 across the 5 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Centro Cardiologico Monzino is the lead sponsor of 72 studies on the registry; 26 are open to participants now.
1 of the studies in Coronary Artery Disease by Centro Cardiologico Monzino that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06410690Centro Cardiologico MonzinoTrustworthy, Integrated Artificial Intelligence Tools for Predicting High-risk CORonary PlaqueS | 2026-11-30 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Coronary Artery Disease by Centro Cardiologico Monzino, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective, single-center interventional imaging study aims to evaluate the diagnostic performance of Photon Counting Computed Tomography (PCCT) combined with artificial intelligence-based Quantitative Coronary CT (AI-QCT) analysis in patients with suspected or known coronary artery disease (CAD).
Adult patients with a positive conventional coronary CT angiography (CCTA) who are scheduled for clinically indicated invasive coronary angiography with intravascular ultrasound (IVUS) will undergo an additional PCCT acquisition for research purposes. PCCT datasets will be analyzed using a dedicated post-processing platform implementing artificial intelligence-based Quantitative Coronary CT (AI-QCT) algorithms for automated plaque quantification and characterization, including assessment of plaque burden, plaque composition, stenosis severity, and high risk plaque features. Conventional CCTA and PCCT images will be compared within the same patient to assess image quality, coronary stenosis, plaque burden and composition, high-risk plaque features, CAD-RADS classification, radiation exposure, and contrast medium volume.
Invasive coronary angiography and IVUS findings will serve as reference standards to evaluate the diagnostic accuracy and agreement of CT-derived measurements. The study will assess whether PCCT combined with AI-QCT provides improved coronary plaque characterization, diagnostic performance, and cardiovascular risk stratification compared with conventional CCTA, while potentially reducing radiation exposure and contrast medium requirements.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with suspected or known coronary artery disease and a positive conventional coronary CT angiography (CCTA) will undergo an additional Photon Counting Computed Tomography (PCCT) acquisition for research purposes. PCCT images will be analyzed using a dedicated image post-processing platform incorporating artificial intelligence-based Quantitative Coronary CT (AI-QCT) algorithms for the assessment of coronary stenosis, plaque burden, plaque composition, and high-risk plaque features. PCCT findings will be compared with conventional CCTA findings and with invasive coronary angiography and intravascular ultrasound (IVUS), which will serve as reference standards.
Radiation: Photon Counting Computed Tomography (PCCT)
Participants will undergo an additional Photon Counting Computed Tomography (PCCT) coronary angiography acquisition for research purposes after a clinically performed conventional coronary CT angiography. The PCCT examination will be performed using an optimized low-dose acquisition protocol. PCCT images will be analyzed using a dedicated image post-processing platform incorporating artificial intelligence-based Quantitative Coronary CT (AI-QCT) algorithms for quantitative and qualitative assessment of coronary artery disease, including coronary stenosis, plaque burden, plaque composition, and high-risk plaque features. Image quality, radiation exposure, and contrast medium volume will also be assessed.
Diagnostic performance of PCCT combined with AI-QCT compared with conventional CCTA
Diagnostic performance of PCCT combined with AI-QCT for the detection and assessment of coronary artery disease, compared with conventional CCTA.
Time frame: 16 months
Signal-to-noise ratio (SNR)
Signal-to-noise ratio measured on conventional CCTA and PCCT images
Time frame: 16 months
Quantitative and qualitative coronary plaque characteristics measured by AI-QCT
Plaque burden, plaque composition, and high-risk plaque features measured by AI-QCT on conventional CCTA and PCCT images.
Time frame: 16 months
Radiation dose associated with conventional CCTA and PCCT
Radiation dose recorded for conventional CCTA and PCCT acquisitions.
Time frame: 16 months
CAD-RADS classification
CAD-RADS classification assigned to conventional CCTA and PCCT datasets.
Time frame: 16 months
Agreement between AI-QCT and IVUS measurements of coronary plaque
Agreement between non-invasive AI-QCT-derived measurements and corresponding invasive IVUS measurements of coronary plaque, assessed using intraclass correlation coefficient (ICC).
Time frame: 16 months
Incremental value of PCCT for cardiovascular risk stratification
Evaluation of the incremental value of PCCT combined with AI-QCT compared with conventional CCTA for cardiovascular risk stratification and clinical decision making.
Time frame: 16 months
Contrast-to-noise ratio (CNR)
Contrast-to-noise ratio measured on conventional CCTA and PCCT images.
Time frame: 16 months
Started Sep 2026 (actual). Primary completion is estimated for Jan 2028, 16 months after the start.
Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 16 months is below that.
Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centro Cardiologico Monzino